Virios therapeutics announces fourth quarter and full year 2021 financial results and provides corporate update

Atlanta--(business wire)---- $viri #biotech--virios therapeutics, inc. (nasdaq: viri), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases including fibromyalgia, today announced financial results for the fourth quarter and full year ended december 31, 2021. key highlights phase 2b fortress fibromyalgia study top line results on track for q3 2022 chronic toxicology studies, required for imc-1 phase 3 studies, are progressing as planned and synchronize
VIRI Ratings Summary
VIRI Quant Ranking